Serafino Pantano

Serafino Pantano has a diverse work experience in the field of clinical biomarker development and precision medicine. Serafino is currently serving as the Head of Clinical Biomarker Development at ADC Therapeutics since 2021. Prior to this, they held various roles at different companies including MSD, Novartis Oncology, Roche, and Novartis. Serafino'sresponsibilities included leading biomarker and diagnostic initiatives, directing precision medicine programs, and serving as a group leader in research. Serafino also has prior experience as a post-doc fellow at the University of Lausanne and the Institute for Research in Biomedicine, as well as a visiting fellow at the NIH.

Serafino Pantano obtained their PhD from Alma Mater Studiorum – Università di Bologna, where the specific field of study is not mentioned. In 2017, they received a Certificate of Advanced Studies in Management of Biotech, Medtech & Pharma Ventures from EPFL (École polytechnique fédérale de Lausanne).